Low-dose cholinesterase inhibitors do not induce delayed effects on cerebral blood flow and metabolism

Pharmacology Biochemistry and Behavior

Volumn 80, Issue 4, 2005, Pages 529-540

  Scremin, Oscar U ^a,c   Shih, Tsung Ming ^b   Huynh, Ly ^a   Roch, Margareth ^a   Sun, Wei ^a   Chialvo, Dante R ^a,c   Jenden, Donald J ^c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cerebral glucose utilization; Cerebrovascular circulation; Low dose cholinesterase toxicity; Nerve agents; Pyridostigmine bromide; Sarin

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; PYRIDOSTIGMINE; SARIN; GLUCOSE;

ANIMAL MODEL; ARTERIAL GAS; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; BRAIN BLOOD FLOW; BRAIN CIRCULATION; CHOLINESTERASE BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE UTILIZATION; INTOXICATION; LD 50; MALE; MEAN ARTERIAL PRESSURE; NEOCORTEX; NONHUMAN; OLFACTORY CORTEX; PH; PRIORITY JOURNAL; RAT; ANIMAL; AUTORADIOGRAPHY; BLOOD; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BRAIN LEVEL; ENZYMOLOGY; ERYTHROCYTE; METABOLISM; REGRESSION ANALYSIS; SPRAGUE DAWLEY RAT;

ANIMALIA;

ANIMALS; AUTORADIOGRAPHY; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BODY TEMPERATURE; BRAIN CHEMISTRY; CEREBROVASCULAR CIRCULATION; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; ERYTHROCYTES; GLUCOSE; HYDROGEN-ION CONCENTRATION; MALE; PYRIDOSTIGMINE BROMIDE; RATS; RATS, SPRAGUE-DAWLEY; REGRESSION ANALYSIS; SARIN;

EID: 22444439362     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.12.013     Document Type: Article

References (48)

1. Bernatova I, Dubovicky M, Price WA, Grubbs RD, Lucot JB, Morris M. Effect of chronic pyridostigmine bromide treatment on cardiovascular and behavioral parameters in mice. Pharmacol Biochem Behav 2003;74:901-7.
2. Blin J, Ivanoiu A, Coppens A, De Voider A, Labar D, Michel C, et al. Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients. NeuroImage 1997;6:335-43.
3. Buccafusco JJ. The role of central cholinergic neurons in the regulation of blood pressure and in experimental hypertension. Pharmacol Rev 1996;48:179-211.
4. Burchfield JL, Duffy FH. Organophosphate neurotoxicity: chronic effects of sarin on the electroencephalogram of monkey and man. Neurobehav Toxicol Teratol 1982;4:767-78.
5. Chambers HW. Organophosphorus compounds: an overview. In: Chambers HW, Levy P, editors. Organophosphates: Chemistry, Fate and Effects. San Diego: Academic Press; 1992. p. 3-17.
6. Chaney LA, Rockhold RW, Hume AS. Cardiorespiratory effects following acute exposure to pyridostigmine bromide and/or N,N-diethyl-m-toluamide (DEBT) in rats. Int J Toxicol 2002;21:287-300.
7. Coordinating Subcommittee. Possible long term health effects of short term exposure to chemical agents, vol III, Final Report, Current health status of test subjects. Committee on Toxicology, Board on Toxicology and Environmental Health Hazards, Assembly of Life Sciences, National Academy Press; 1985.
8. Ecobichon DJ, Joy RM. Pesticides and Neurological Diseases. Boca Raton, Florida: CRC Press, Inc.; 1982.
9. Ellman GL, Courtney KD, Andres Jr. V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
10. Fox PT, Raichle ME. Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc Natl Acad Sci U S A 1986;83:1140-4.
11. Freireich EJ, Gehan EA, Ral DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
12. Gallistel CR, Nichols S. Resolution-limiting factors in 2-deoxyglucose autoradiography: I. Factors other than diffusion. Brain Res 1983; 267:323-33.
13. Gsell W, De Sadeleer C, Marchalant Y, MacKenzie ET, Schumann P, Dauphin F. The use of cerebral blood flow as an index of neuronal activity in functional neuroimaging: experimental and pathophysiological considerations. J Chem Neuroanat 2000;20:215-24.
14. Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides 2001;22:995-1007.
15. Holschneider DP, Maarek JM, Yang J, Harimoto J, Scremin OU. Functional brain mapping in freely moving rats during treadmill walking. J Cereb Blood Flow Metab 2003;23:925-32.
16. Joaquim LF, Farah VM, Bernatova I, Fazan Jr R, Grubbs R, Morris M. Enhanced heart rate variability and baroreflex index after stress and cholinesterase inhibition in mice. Am J Physiol, Heart Circ Physiol 2004;287:H251-7.
17. Keeler JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 1991;266:693-5.
18. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6: 1258-66.
19. Lucas-Meunier E, Fossier P, Baux G, Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch 2003;446:17-29.
20. McCauley LA, Rischitelli G, Lambert WE, Lasarev M, Sticker DL, Spencer PS. Symptoms of Gulf War veterans possibly exposed to organophosphate chemical warfare agents at Khamisiyah, Iraq. Int J Occup Environ Health 2001;7:79-89.
21. McCulloch J. Mapping functional alterations in the CNS with [C14]deoxyglucose. In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of Psychopharmacology. New Techniques in Psychopharmacology, vol. 15. New York: Plenum Press; 1982. p. 321-409.
22. Moore DH. Health effects of exposure to low doses of nerve agent - a review of present knowledge. Drug Chem Toxicol 1998;21:123-30.
23. Panel on Anticholinesterase Chemicals. Possible long term health effects of short term exposure to chemical agents. Anticholinesterases and anticholinergics. Committee on Toxicology and Environmental Health Hazards, Assembly of Life Sciences, vol I. Washington: National Academy Press; 1982.
24. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic Press; 1998.
25. Reivich M, Jehle J, Sokoloff L, Kety SS. Measurement of regional cerebral blood flow with antipyrine-[14C] in awake cats. J Appl Physiol 1969;27:296-300.
26. Roberson MR, Schmidt MB, Gonzales MD, McDonough JH. The effects of chronic, low-dose sarin exposure on behavior, neurochemistry, and brain pathology. Soc Neurosci Abstr 2001;27:971.1:2582.
27. Russell RW, Booth RA, Lauretz SD, Smith CA, Jenden DJ. Behavioural, neurochemical and physiological effects of repeated exposures to subsymptomatic levels of the anticholinesterase, soman. Neurobehav Toxicol Teratol 1986;8:675-85.
28. Sakurada O, Kennedy C, Jehle J, Brown JD, Carbin GL, Sokoloff L. Measurement of local cerebral blood flow with iodo[14C]antipyrine. Am J Physiol 1978;234:H59-66.
29. Scremin OU. Pharmacological control of the cerebral circulation. Annu Rev Pharmacol Toxicol 1991;31:229-51.
30. Scremin OU. Cholinergic control of cerebral blood flow. In: Phillis JW, editor. The Regulation of Cerebral Blood Flow. Boca Raton, Florida: CRC Press; 1993. p. 129-35.
31. Scremin OU. Cerebral vascular system. In: Paxinos G, Mai J, editors. The Human Brain. Sidney: Elsevier; 2003. p. 1326-48.
32. Scremin OU, Jenden DJ. Cholinergic control of cerebral blood flow in stroke, trauma and aging. Life Sci 1996;58:2011-8.
33. Scremin OU, Shih T-M. Cerebral blood flow-metabolism coupling after administration of soman at nontoxic levels. Brain Res Bull 1991; 26:353-6.
34. Scremin OU, Sonnenschein RR, Rubinstein EH. Cholinergic cerebral vasodilatation in the rabbit: absence of concomitant metabolic activation. J Cereb Blood Flow Metab 1982;2:241-7.
35. Scremin OU, Allen K, Torres CD, Scremin AME. Physostigmine enhances blood flow metabolism ratio in neocortex. Neuropsychopharmacology 1988;1(4):297-303.
36. Scremin OU, Scremin AME, Heuser D, Hudgell R, Romero E, Imbimbo B. Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats. J Cereb Blood Flow Metab 1993;13:702-11.
37. Scremin OU, Shih T-M, Huynh L, Roch M, Booth R, Jenden DJ. Delayed neurologic and behavioral effects of subtoxic doses of cholinesterase inhibitors. J Pharmacol Exp Ther 2003;304:1111-9.
38. Servatius RJ, Ottenweller JE, Beldowicz D, Guo W, Zhu G, Natelson BH. Persistently exaggerated startle responses in rats treated with pyridostigmine bromide. J Pharmacol Exp Ther 1998;287:1020-8.
39. Shih T-M. Effects of soman on blood and regional brain cholinesterase activities. Trans Am Soc Neurochem 1983;14:148.
40. Shih T-M, Romano JA. The effects of choline on soman-induced analgesia and toxicity. Neurotoxicol Teratol 1988;10(4):287-94.
41. Shih T-M, Scremin OU. Cerebral blood flow and metabolism in soman-induced convulsions. Brain Res Bull 1992;28:735-42.
42. Shih T-M, Lenz DE, Maxwell DM. Effects of repeated injection of sublethal doses of soman on behavior and on brain acetylcholine and choline concentration in the rat. Psychopharmacology 1990;101: 489-96.
43. Sidell FR. Soman and Sarin: Clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol 1974;7:1-17.
44. Snedecor GW, Cochran WG. Statistical methods. Ames, Iowa: The Iowa State University Press; 1980.
45. Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab 1981;1:7-36.
46. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [14]C-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized normal rat. J Neurochem 1977;28:897-916.
47. Stein RD, Backman SB, Collier B, Polosa C. Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth 1997;44:1286-92.
48. Varagic V. The action of eserine on the blood pressure of the rat. Br J Pharmacol 1955;10:349-53.